Clinical and Translational Medicine-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2103709, encodeId=819f2103e0902, content=请教大家一个问题，这个杂志编辑部要求上传以前的投稿版本和查重报告，但是PDF格式一直上传不了，大家是怎么解决这个问题的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=210, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27ce8200339, createdName=ms3000001959437613, createdTime=Thu Dec 01 14:06:25 CST 2022, time=2022-12-01, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2233938, encodeId=20572233938c9, content=偏重的研究方向：骨科 经验分享：大伙儿们，这个杂志是提交后状态就是under review吗？已经一个月了，期间也没收到送审的邮件，状态一直是under review, 很焦虑。<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>#clinical and translational medicine#, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=10, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c43b9111664, createdName=ms9000000165099070, createdTime=Tue Oct 29 15:31:03 CST 2024, time=2024-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2198461, encodeId=a741219846107, content=偏重的研究方向：肿瘤;肿瘤临床基础;癌症治疗 经验分享：2024.1.8投稿 under initial checking 2024.1.13变为under review 2024.1.25变为pending recommendation 2024.2.6变为major revision，三个审稿人，两个小修一个大修，编辑给了大修，给了两个月时间。每个审稿人5个左右问题，补了两个大实验，现在已返修回去，求好运…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=235, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ca15460308, createdName=ms3000001338909804, createdTime=Sun Apr 14 16:14:56 CST 2024, time=2024-04-14, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2188951, encodeId=82882188951ff, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：神经系统疾病 经验分享：审稿人偏多，一般5-6个（可能同时找10几个） 01-Nov-2023 submit； 25-Nov-2023 major revision（五个审稿人，给两个月时间）； 30-Jan-2024 revision submit； 19-Feb-2024 minor revision（二审加送一个审稿人）； 21-Feb-2024 revision submit； 22-Feb-2024 accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6a62307215, createdName=科研小白白白白alz, createdTime=Fri Feb 23 18:09:13 CST 2024, time=2024-02-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2255223, encodeId=863c2255223e3, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：速度挺快投稿到接受 4 个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b13f1619698, createdName=ZF2012ZF, createdTime=Sat Mar 08 16:13:50 CST 2025, time=2025-03-08, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2247883, encodeId=b60a224e883d8, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫治疗;非小细胞肺癌;微生物组学 经验分享：Issue Online: 10 January 2025 Version of Record online: 10 January 2025（接收后约20天online） Manuscript accepted: 22 December 2024 Manuscript revised: 09 December 2024 Need Revision: 02 December 2024(二审2个月，增加1位审稿人，8条审稿意见) Under Review: 08 October 2024(一个审稿人，14条审稿意见，相对容易回答) Need Revision: 07 October 2024(一审1个月) Manuscript received: 05 September 2024 整体审稿速度适中，审稿意见相对柔和，较容易回答，一审速度快前提是未找到足够多的审稿人的情况下 APC约2.7wRMB（当日汇率计算），接收后在线proof，约20天online。希望对大家有用。加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f8c1744425, createdName=2122015030, createdTime=Mon Jan 13 14:35:58 CST 2025, time=2025-01-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2101296, encodeId=1ed62101296f2, content=请问大佬们在under review之前有经过pending decision吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b918193010, createdName=ms8000000534826025, createdTime=Fri Nov 18 11:33:30 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2227813, encodeId=c63f222e813de, content=投稿两天，投稿submission status 是under review，但是右边有几行小字写的是This submission is under consideration and cannot be edited. Further information will be emailed to you by the journal editorial office.，求问这是送审了还是还没分配编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d905570358, createdName=ms3000001344629820, createdTime=Thu Sep 26 15:11:46 CST 2024, time=2024-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=953692, encodeId=8aea953692bb, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：第一次投稿没有送外审被编辑直接拒稿但是副编辑给了修改为letter重新投的机会于是修改为letter后重新投稿送外审一审一个月左右小修修回后三天左右接收很快online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=334, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2bf35329265, createdName=148c69cbm40暂无昵称, createdTime=Sat Apr 03 23:54:59 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2243716, encodeId=15f82243e1608, content=偏重的研究方向：肿瘤 经验分享：杂志一般，类似international journal of surgery，及时if8，希望后续能维持10, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=83912531155, createdName=1250080bm96暂无昵称, createdTime=Fri Dec 20 10:51:30 CST 2024, time=2024-12-20, status=1, ipAttribution=北京)]

2022-12-01 ms3000001959437613 来自湖北省

请教大家一个问题，这个杂志编辑部要求上传以前的投稿版本和查重报告，但是PDF格式一直上传不了，大家是怎么解决这个问题的？

210 3 举报

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2103709, encodeId=819f2103e0902, content=请教大家一个问题，这个杂志编辑部要求上传以前的投稿版本和查重报告，但是PDF格式一直上传不了，大家是怎么解决这个问题的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=210, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27ce8200339, createdName=ms3000001959437613, createdTime=Thu Dec 01 14:06:25 CST 2022, time=2022-12-01, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2233938, encodeId=20572233938c9, content=偏重的研究方向：骨科 经验分享：大伙儿们，这个杂志是提交后状态就是under review吗？已经一个月了，期间也没收到送审的邮件，状态一直是under review, 很焦虑。<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>#clinical and translational medicine#, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=10, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c43b9111664, createdName=ms9000000165099070, createdTime=Tue Oct 29 15:31:03 CST 2024, time=2024-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2198461, encodeId=a741219846107, content=偏重的研究方向：肿瘤;肿瘤临床基础;癌症治疗 经验分享：2024.1.8投稿 under initial checking 2024.1.13变为under review 2024.1.25变为pending recommendation 2024.2.6变为major revision，三个审稿人，两个小修一个大修，编辑给了大修，给了两个月时间。每个审稿人5个左右问题，补了两个大实验，现在已返修回去，求好运…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=235, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ca15460308, createdName=ms3000001338909804, createdTime=Sun Apr 14 16:14:56 CST 2024, time=2024-04-14, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2188951, encodeId=82882188951ff, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：神经系统疾病 经验分享：审稿人偏多，一般5-6个（可能同时找10几个） 01-Nov-2023 submit； 25-Nov-2023 major revision（五个审稿人，给两个月时间）； 30-Jan-2024 revision submit； 19-Feb-2024 minor revision（二审加送一个审稿人）； 21-Feb-2024 revision submit； 22-Feb-2024 accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6a62307215, createdName=科研小白白白白alz, createdTime=Fri Feb 23 18:09:13 CST 2024, time=2024-02-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2255223, encodeId=863c2255223e3, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：速度挺快投稿到接受 4 个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b13f1619698, createdName=ZF2012ZF, createdTime=Sat Mar 08 16:13:50 CST 2025, time=2025-03-08, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2247883, encodeId=b60a224e883d8, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫治疗;非小细胞肺癌;微生物组学 经验分享：Issue Online: 10 January 2025 Version of Record online: 10 January 2025（接收后约20天online） Manuscript accepted: 22 December 2024 Manuscript revised: 09 December 2024 Need Revision: 02 December 2024(二审2个月，增加1位审稿人，8条审稿意见) Under Review: 08 October 2024(一个审稿人，14条审稿意见，相对容易回答) Need Revision: 07 October 2024(一审1个月) Manuscript received: 05 September 2024 整体审稿速度适中，审稿意见相对柔和，较容易回答，一审速度快前提是未找到足够多的审稿人的情况下 APC约2.7wRMB（当日汇率计算），接收后在线proof，约20天online。希望对大家有用。加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f8c1744425, createdName=2122015030, createdTime=Mon Jan 13 14:35:58 CST 2025, time=2025-01-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2101296, encodeId=1ed62101296f2, content=请问大佬们在under review之前有经过pending decision吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b918193010, createdName=ms8000000534826025, createdTime=Fri Nov 18 11:33:30 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2227813, encodeId=c63f222e813de, content=投稿两天，投稿submission status 是under review，但是右边有几行小字写的是This submission is under consideration and cannot be edited. Further information will be emailed to you by the journal editorial office.，求问这是送审了还是还没分配编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d905570358, createdName=ms3000001344629820, createdTime=Thu Sep 26 15:11:46 CST 2024, time=2024-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=953692, encodeId=8aea953692bb, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：第一次投稿没有送外审被编辑直接拒稿但是副编辑给了修改为letter重新投的机会于是修改为letter后重新投稿送外审一审一个月左右小修修回后三天左右接收很快online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=334, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2bf35329265, createdName=148c69cbm40暂无昵称, createdTime=Sat Apr 03 23:54:59 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2243716, encodeId=15f82243e1608, content=偏重的研究方向：肿瘤 经验分享：杂志一般，类似international journal of surgery，及时if8，希望后续能维持10, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=83912531155, createdName=1250080bm96暂无昵称, createdTime=Fri Dec 20 10:51:30 CST 2024, time=2024-12-20, status=1, ipAttribution=北京)]

2024-10-29 ms9000000165099070

偏重的研究方向：骨科
经验分享：大伙儿们，这个杂志是提交后状态就是under review吗？已经一个月了，期间也没收到送审的邮件，状态一直是under review, 很焦虑。#期刊论坛##clinical and translational medicine#

203 10 举报

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=2103709, encodeId=819f2103e0902, content=请教大家一个问题，这个杂志编辑部要求上传以前的投稿版本和查重报告，但是PDF格式一直上传不了，大家是怎么解决这个问题的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=210, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27ce8200339, createdName=ms3000001959437613, createdTime=Thu Dec 01 14:06:25 CST 2022, time=2022-12-01, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2233938, encodeId=20572233938c9, content=偏重的研究方向：骨科 经验分享：大伙儿们，这个杂志是提交后状态就是under review吗？已经一个月了，期间也没收到送审的邮件，状态一直是under review, 很焦虑。<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>#clinical and translational medicine#, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=10, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c43b9111664, createdName=ms9000000165099070, createdTime=Tue Oct 29 15:31:03 CST 2024, time=2024-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2198461, encodeId=a741219846107, content=偏重的研究方向：肿瘤;肿瘤临床基础;癌症治疗 经验分享：2024.1.8投稿 under initial checking 2024.1.13变为under review 2024.1.25变为pending recommendation 2024.2.6变为major revision，三个审稿人，两个小修一个大修，编辑给了大修，给了两个月时间。每个审稿人5个左右问题，补了两个大实验，现在已返修回去，求好运…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=235, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ca15460308, createdName=ms3000001338909804, createdTime=Sun Apr 14 16:14:56 CST 2024, time=2024-04-14, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2188951, encodeId=82882188951ff, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：神经系统疾病 经验分享：审稿人偏多，一般5-6个（可能同时找10几个） 01-Nov-2023 submit； 25-Nov-2023 major revision（五个审稿人，给两个月时间）； 30-Jan-2024 revision submit； 19-Feb-2024 minor revision（二审加送一个审稿人）； 21-Feb-2024 revision submit； 22-Feb-2024 accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6a62307215, createdName=科研小白白白白alz, createdTime=Fri Feb 23 18:09:13 CST 2024, time=2024-02-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2255223, encodeId=863c2255223e3, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：速度挺快投稿到接受 4 个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b13f1619698, createdName=ZF2012ZF, createdTime=Sat Mar 08 16:13:50 CST 2025, time=2025-03-08, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2247883, encodeId=b60a224e883d8, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫治疗;非小细胞肺癌;微生物组学 经验分享：Issue Online: 10 January 2025 Version of Record online: 10 January 2025（接收后约20天online） Manuscript accepted: 22 December 2024 Manuscript revised: 09 December 2024 Need Revision: 02 December 2024(二审2个月，增加1位审稿人，8条审稿意见) Under Review: 08 October 2024(一个审稿人，14条审稿意见，相对容易回答) Need Revision: 07 October 2024(一审1个月) Manuscript received: 05 September 2024 整体审稿速度适中，审稿意见相对柔和，较容易回答，一审速度快前提是未找到足够多的审稿人的情况下 APC约2.7wRMB（当日汇率计算），接收后在线proof，约20天online。希望对大家有用。加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f8c1744425, createdName=2122015030, createdTime=Mon Jan 13 14:35:58 CST 2025, time=2025-01-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2101296, encodeId=1ed62101296f2, content=请问大佬们在under review之前有经过pending decision吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b918193010, createdName=ms8000000534826025, createdTime=Fri Nov 18 11:33:30 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2227813, encodeId=c63f222e813de, content=投稿两天，投稿submission status 是under review，但是右边有几行小字写的是This submission is under consideration and cannot be edited. Further information will be emailed to you by the journal editorial office.，求问这是送审了还是还没分配编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d905570358, createdName=ms3000001344629820, createdTime=Thu Sep 26 15:11:46 CST 2024, time=2024-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=953692, encodeId=8aea953692bb, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：第一次投稿没有送外审被编辑直接拒稿但是副编辑给了修改为letter重新投的机会于是修改为letter后重新投稿送外审一审一个月左右小修修回后三天左右接收很快online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=334, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2bf35329265, createdName=148c69cbm40暂无昵称, createdTime=Sat Apr 03 23:54:59 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2243716, encodeId=15f82243e1608, content=偏重的研究方向：肿瘤 经验分享：杂志一般，类似international journal of surgery，及时if8，希望后续能维持10, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=83912531155, createdName=1250080bm96暂无昵称, createdTime=Fri Dec 20 10:51:30 CST 2024, time=2024-12-20, status=1, ipAttribution=北京)]

2024-04-14 ms3000001338909804 来自湖北省

偏重的研究方向：肿瘤;肿瘤临床基础;癌症治疗
经验分享：2024.1.8投稿 under initial checking 2024.1.13变为under review 2024.1.25变为pending recommendation 2024.2.6变为major revision，三个审稿人，两个小修一个大修，编辑给了大修，给了两个月时间。每个审稿人5个左右问题，补了两个大实验，现在已返修回去，求好运…

235 19 举报

展开19条回复

[GetPortalCommentsPageByObjectIdResponse(id=2103709, encodeId=819f2103e0902, content=请教大家一个问题，这个杂志编辑部要求上传以前的投稿版本和查重报告，但是PDF格式一直上传不了，大家是怎么解决这个问题的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=210, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27ce8200339, createdName=ms3000001959437613, createdTime=Thu Dec 01 14:06:25 CST 2022, time=2022-12-01, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2233938, encodeId=20572233938c9, content=偏重的研究方向：骨科 经验分享：大伙儿们，这个杂志是提交后状态就是under review吗？已经一个月了，期间也没收到送审的邮件，状态一直是under review, 很焦虑。<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>#clinical and translational medicine#, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=10, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c43b9111664, createdName=ms9000000165099070, createdTime=Tue Oct 29 15:31:03 CST 2024, time=2024-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2198461, encodeId=a741219846107, content=偏重的研究方向：肿瘤;肿瘤临床基础;癌症治疗 经验分享：2024.1.8投稿 under initial checking 2024.1.13变为under review 2024.1.25变为pending recommendation 2024.2.6变为major revision，三个审稿人，两个小修一个大修，编辑给了大修，给了两个月时间。每个审稿人5个左右问题，补了两个大实验，现在已返修回去，求好运…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=235, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ca15460308, createdName=ms3000001338909804, createdTime=Sun Apr 14 16:14:56 CST 2024, time=2024-04-14, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2188951, encodeId=82882188951ff, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：神经系统疾病 经验分享：审稿人偏多，一般5-6个（可能同时找10几个） 01-Nov-2023 submit； 25-Nov-2023 major revision（五个审稿人，给两个月时间）； 30-Jan-2024 revision submit； 19-Feb-2024 minor revision（二审加送一个审稿人）； 21-Feb-2024 revision submit； 22-Feb-2024 accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6a62307215, createdName=科研小白白白白alz, createdTime=Fri Feb 23 18:09:13 CST 2024, time=2024-02-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2255223, encodeId=863c2255223e3, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：速度挺快投稿到接受 4 个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b13f1619698, createdName=ZF2012ZF, createdTime=Sat Mar 08 16:13:50 CST 2025, time=2025-03-08, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2247883, encodeId=b60a224e883d8, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫治疗;非小细胞肺癌;微生物组学 经验分享：Issue Online: 10 January 2025 Version of Record online: 10 January 2025（接收后约20天online） Manuscript accepted: 22 December 2024 Manuscript revised: 09 December 2024 Need Revision: 02 December 2024(二审2个月，增加1位审稿人，8条审稿意见) Under Review: 08 October 2024(一个审稿人，14条审稿意见，相对容易回答) Need Revision: 07 October 2024(一审1个月) Manuscript received: 05 September 2024 整体审稿速度适中，审稿意见相对柔和，较容易回答，一审速度快前提是未找到足够多的审稿人的情况下 APC约2.7wRMB（当日汇率计算），接收后在线proof，约20天online。希望对大家有用。加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f8c1744425, createdName=2122015030, createdTime=Mon Jan 13 14:35:58 CST 2025, time=2025-01-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2101296, encodeId=1ed62101296f2, content=请问大佬们在under review之前有经过pending decision吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b918193010, createdName=ms8000000534826025, createdTime=Fri Nov 18 11:33:30 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2227813, encodeId=c63f222e813de, content=投稿两天，投稿submission status 是under review，但是右边有几行小字写的是This submission is under consideration and cannot be edited. Further information will be emailed to you by the journal editorial office.，求问这是送审了还是还没分配编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d905570358, createdName=ms3000001344629820, createdTime=Thu Sep 26 15:11:46 CST 2024, time=2024-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=953692, encodeId=8aea953692bb, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：第一次投稿没有送外审被编辑直接拒稿但是副编辑给了修改为letter重新投的机会于是修改为letter后重新投稿送外审一审一个月左右小修修回后三天左右接收很快online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=334, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2bf35329265, createdName=148c69cbm40暂无昵称, createdTime=Sat Apr 03 23:54:59 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2243716, encodeId=15f82243e1608, content=偏重的研究方向：肿瘤 经验分享：杂志一般，类似international journal of surgery，及时if8，希望后续能维持10, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=83912531155, createdName=1250080bm96暂无昵称, createdTime=Fri Dec 20 10:51:30 CST 2024, time=2024-12-20, status=1, ipAttribution=北京)]

2024-02-23 科研小白白白白alz 来自湖北省

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：神经系统疾病
经验分享：审稿人偏多，一般5-6个（可能同时找10几个）
01-Nov-2023 submit；
25-Nov-2023 major revision（五个审稿人，给两个月时间）；
30-Jan-2024 revision submit；
19-Feb-2024 minor revision（二审加送一个审稿人）；
21-Feb-2024 revision submit；
22-Feb-2024 accept

327 15 举报

展开15条回复

[GetPortalCommentsPageByObjectIdResponse(id=2103709, encodeId=819f2103e0902, content=请教大家一个问题，这个杂志编辑部要求上传以前的投稿版本和查重报告，但是PDF格式一直上传不了，大家是怎么解决这个问题的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=210, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27ce8200339, createdName=ms3000001959437613, createdTime=Thu Dec 01 14:06:25 CST 2022, time=2022-12-01, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2233938, encodeId=20572233938c9, content=偏重的研究方向：骨科 经验分享：大伙儿们，这个杂志是提交后状态就是under review吗？已经一个月了，期间也没收到送审的邮件，状态一直是under review, 很焦虑。<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>#clinical and translational medicine#, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=10, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c43b9111664, createdName=ms9000000165099070, createdTime=Tue Oct 29 15:31:03 CST 2024, time=2024-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2198461, encodeId=a741219846107, content=偏重的研究方向：肿瘤;肿瘤临床基础;癌症治疗 经验分享：2024.1.8投稿 under initial checking 2024.1.13变为under review 2024.1.25变为pending recommendation 2024.2.6变为major revision，三个审稿人，两个小修一个大修，编辑给了大修，给了两个月时间。每个审稿人5个左右问题，补了两个大实验，现在已返修回去，求好运…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=235, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ca15460308, createdName=ms3000001338909804, createdTime=Sun Apr 14 16:14:56 CST 2024, time=2024-04-14, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2188951, encodeId=82882188951ff, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：神经系统疾病 经验分享：审稿人偏多，一般5-6个（可能同时找10几个） 01-Nov-2023 submit； 25-Nov-2023 major revision（五个审稿人，给两个月时间）； 30-Jan-2024 revision submit； 19-Feb-2024 minor revision（二审加送一个审稿人）； 21-Feb-2024 revision submit； 22-Feb-2024 accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6a62307215, createdName=科研小白白白白alz, createdTime=Fri Feb 23 18:09:13 CST 2024, time=2024-02-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2255223, encodeId=863c2255223e3, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：速度挺快投稿到接受 4 个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b13f1619698, createdName=ZF2012ZF, createdTime=Sat Mar 08 16:13:50 CST 2025, time=2025-03-08, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2247883, encodeId=b60a224e883d8, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫治疗;非小细胞肺癌;微生物组学 经验分享：Issue Online: 10 January 2025 Version of Record online: 10 January 2025（接收后约20天online） Manuscript accepted: 22 December 2024 Manuscript revised: 09 December 2024 Need Revision: 02 December 2024(二审2个月，增加1位审稿人，8条审稿意见) Under Review: 08 October 2024(一个审稿人，14条审稿意见，相对容易回答) Need Revision: 07 October 2024(一审1个月) Manuscript received: 05 September 2024 整体审稿速度适中，审稿意见相对柔和，较容易回答，一审速度快前提是未找到足够多的审稿人的情况下 APC约2.7wRMB（当日汇率计算），接收后在线proof，约20天online。希望对大家有用。加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f8c1744425, createdName=2122015030, createdTime=Mon Jan 13 14:35:58 CST 2025, time=2025-01-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2101296, encodeId=1ed62101296f2, content=请问大佬们在under review之前有经过pending decision吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b918193010, createdName=ms8000000534826025, createdTime=Fri Nov 18 11:33:30 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2227813, encodeId=c63f222e813de, content=投稿两天，投稿submission status 是under review，但是右边有几行小字写的是This submission is under consideration and cannot be edited. Further information will be emailed to you by the journal editorial office.，求问这是送审了还是还没分配编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d905570358, createdName=ms3000001344629820, createdTime=Thu Sep 26 15:11:46 CST 2024, time=2024-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=953692, encodeId=8aea953692bb, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：第一次投稿没有送外审被编辑直接拒稿但是副编辑给了修改为letter重新投的机会于是修改为letter后重新投稿送外审一审一个月左右小修修回后三天左右接收很快online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=334, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2bf35329265, createdName=148c69cbm40暂无昵称, createdTime=Sat Apr 03 23:54:59 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2243716, encodeId=15f82243e1608, content=偏重的研究方向：肿瘤 经验分享：杂志一般，类似international journal of surgery，及时if8，希望后续能维持10, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=83912531155, createdName=1250080bm96暂无昵称, createdTime=Fri Dec 20 10:51:30 CST 2024, time=2024-12-20, status=1, ipAttribution=北京)]

2025-03-08 ZF2012ZF 来自浙江省

审稿速度:3.0 | 投稿命中率:50.0
经验分享：速度挺快投稿到接受 4 个月

148 3 举报

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2103709, encodeId=819f2103e0902, content=请教大家一个问题，这个杂志编辑部要求上传以前的投稿版本和查重报告，但是PDF格式一直上传不了，大家是怎么解决这个问题的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=210, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27ce8200339, createdName=ms3000001959437613, createdTime=Thu Dec 01 14:06:25 CST 2022, time=2022-12-01, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2233938, encodeId=20572233938c9, content=偏重的研究方向：骨科 经验分享：大伙儿们，这个杂志是提交后状态就是under review吗？已经一个月了，期间也没收到送审的邮件，状态一直是under review, 很焦虑。<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>#clinical and translational medicine#, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=10, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c43b9111664, createdName=ms9000000165099070, createdTime=Tue Oct 29 15:31:03 CST 2024, time=2024-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2198461, encodeId=a741219846107, content=偏重的研究方向：肿瘤;肿瘤临床基础;癌症治疗 经验分享：2024.1.8投稿 under initial checking 2024.1.13变为under review 2024.1.25变为pending recommendation 2024.2.6变为major revision，三个审稿人，两个小修一个大修，编辑给了大修，给了两个月时间。每个审稿人5个左右问题，补了两个大实验，现在已返修回去，求好运…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=235, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ca15460308, createdName=ms3000001338909804, createdTime=Sun Apr 14 16:14:56 CST 2024, time=2024-04-14, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2188951, encodeId=82882188951ff, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：神经系统疾病 经验分享：审稿人偏多，一般5-6个（可能同时找10几个） 01-Nov-2023 submit； 25-Nov-2023 major revision（五个审稿人，给两个月时间）； 30-Jan-2024 revision submit； 19-Feb-2024 minor revision（二审加送一个审稿人）； 21-Feb-2024 revision submit； 22-Feb-2024 accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6a62307215, createdName=科研小白白白白alz, createdTime=Fri Feb 23 18:09:13 CST 2024, time=2024-02-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2255223, encodeId=863c2255223e3, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：速度挺快投稿到接受 4 个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b13f1619698, createdName=ZF2012ZF, createdTime=Sat Mar 08 16:13:50 CST 2025, time=2025-03-08, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2247883, encodeId=b60a224e883d8, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫治疗;非小细胞肺癌;微生物组学 经验分享：Issue Online: 10 January 2025 Version of Record online: 10 January 2025（接收后约20天online） Manuscript accepted: 22 December 2024 Manuscript revised: 09 December 2024 Need Revision: 02 December 2024(二审2个月，增加1位审稿人，8条审稿意见) Under Review: 08 October 2024(一个审稿人，14条审稿意见，相对容易回答) Need Revision: 07 October 2024(一审1个月) Manuscript received: 05 September 2024 整体审稿速度适中，审稿意见相对柔和，较容易回答，一审速度快前提是未找到足够多的审稿人的情况下 APC约2.7wRMB（当日汇率计算），接收后在线proof，约20天online。希望对大家有用。加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f8c1744425, createdName=2122015030, createdTime=Mon Jan 13 14:35:58 CST 2025, time=2025-01-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2101296, encodeId=1ed62101296f2, content=请问大佬们在under review之前有经过pending decision吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b918193010, createdName=ms8000000534826025, createdTime=Fri Nov 18 11:33:30 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2227813, encodeId=c63f222e813de, content=投稿两天，投稿submission status 是under review，但是右边有几行小字写的是This submission is under consideration and cannot be edited. Further information will be emailed to you by the journal editorial office.，求问这是送审了还是还没分配编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d905570358, createdName=ms3000001344629820, createdTime=Thu Sep 26 15:11:46 CST 2024, time=2024-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=953692, encodeId=8aea953692bb, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：第一次投稿没有送外审被编辑直接拒稿但是副编辑给了修改为letter重新投的机会于是修改为letter后重新投稿送外审一审一个月左右小修修回后三天左右接收很快online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=334, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2bf35329265, createdName=148c69cbm40暂无昵称, createdTime=Sat Apr 03 23:54:59 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2243716, encodeId=15f82243e1608, content=偏重的研究方向：肿瘤 经验分享：杂志一般，类似international journal of surgery，及时if8，希望后续能维持10, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=83912531155, createdName=1250080bm96暂无昵称, createdTime=Fri Dec 20 10:51:30 CST 2024, time=2024-12-20, status=1, ipAttribution=北京)]

2025-01-13 2122015030 来自陕西省

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：免疫治疗;非小细胞肺癌;微生物组学
经验分享：Issue Online: 10 January 2025
Version of Record online: 10 January 2025（接收后约20天online）
Manuscript accepted: 22 December 2024
Manuscript revised: 09 December 2024
Need Revision: 02 December 2024(二审2个月，增加1位审稿人，8条审稿意见)
Under Review: 08 October 2024(一个审稿人，14条审稿意见，相对容易回答)
Need Revision: 07 October 2024(一审1个月)
Manuscript received: 05 September 2024

整体审稿速度适中，审稿意见相对柔和，较容易回答，一审速度快前提是未找到足够多的审稿人的情况下
APC约2.7wRMB（当日汇率计算），接收后在线proof，约20天online。希望对大家有用。加油！

122 3 举报

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2103709, encodeId=819f2103e0902, content=请教大家一个问题，这个杂志编辑部要求上传以前的投稿版本和查重报告，但是PDF格式一直上传不了，大家是怎么解决这个问题的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=210, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27ce8200339, createdName=ms3000001959437613, createdTime=Thu Dec 01 14:06:25 CST 2022, time=2022-12-01, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2233938, encodeId=20572233938c9, content=偏重的研究方向：骨科 经验分享：大伙儿们，这个杂志是提交后状态就是under review吗？已经一个月了，期间也没收到送审的邮件，状态一直是under review, 很焦虑。<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>#clinical and translational medicine#, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=10, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c43b9111664, createdName=ms9000000165099070, createdTime=Tue Oct 29 15:31:03 CST 2024, time=2024-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2198461, encodeId=a741219846107, content=偏重的研究方向：肿瘤;肿瘤临床基础;癌症治疗 经验分享：2024.1.8投稿 under initial checking 2024.1.13变为under review 2024.1.25变为pending recommendation 2024.2.6变为major revision，三个审稿人，两个小修一个大修，编辑给了大修，给了两个月时间。每个审稿人5个左右问题，补了两个大实验，现在已返修回去，求好运…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=235, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ca15460308, createdName=ms3000001338909804, createdTime=Sun Apr 14 16:14:56 CST 2024, time=2024-04-14, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2188951, encodeId=82882188951ff, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：神经系统疾病 经验分享：审稿人偏多，一般5-6个（可能同时找10几个） 01-Nov-2023 submit； 25-Nov-2023 major revision（五个审稿人，给两个月时间）； 30-Jan-2024 revision submit； 19-Feb-2024 minor revision（二审加送一个审稿人）； 21-Feb-2024 revision submit； 22-Feb-2024 accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6a62307215, createdName=科研小白白白白alz, createdTime=Fri Feb 23 18:09:13 CST 2024, time=2024-02-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2255223, encodeId=863c2255223e3, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：速度挺快投稿到接受 4 个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b13f1619698, createdName=ZF2012ZF, createdTime=Sat Mar 08 16:13:50 CST 2025, time=2025-03-08, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2247883, encodeId=b60a224e883d8, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫治疗;非小细胞肺癌;微生物组学 经验分享：Issue Online: 10 January 2025 Version of Record online: 10 January 2025（接收后约20天online） Manuscript accepted: 22 December 2024 Manuscript revised: 09 December 2024 Need Revision: 02 December 2024(二审2个月，增加1位审稿人，8条审稿意见) Under Review: 08 October 2024(一个审稿人，14条审稿意见，相对容易回答) Need Revision: 07 October 2024(一审1个月) Manuscript received: 05 September 2024 整体审稿速度适中，审稿意见相对柔和，较容易回答，一审速度快前提是未找到足够多的审稿人的情况下 APC约2.7wRMB（当日汇率计算），接收后在线proof，约20天online。希望对大家有用。加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f8c1744425, createdName=2122015030, createdTime=Mon Jan 13 14:35:58 CST 2025, time=2025-01-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2101296, encodeId=1ed62101296f2, content=请问大佬们在under review之前有经过pending decision吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b918193010, createdName=ms8000000534826025, createdTime=Fri Nov 18 11:33:30 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2227813, encodeId=c63f222e813de, content=投稿两天，投稿submission status 是under review，但是右边有几行小字写的是This submission is under consideration and cannot be edited. Further information will be emailed to you by the journal editorial office.，求问这是送审了还是还没分配编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d905570358, createdName=ms3000001344629820, createdTime=Thu Sep 26 15:11:46 CST 2024, time=2024-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=953692, encodeId=8aea953692bb, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：第一次投稿没有送外审被编辑直接拒稿但是副编辑给了修改为letter重新投的机会于是修改为letter后重新投稿送外审一审一个月左右小修修回后三天左右接收很快online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=334, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2bf35329265, createdName=148c69cbm40暂无昵称, createdTime=Sat Apr 03 23:54:59 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2243716, encodeId=15f82243e1608, content=偏重的研究方向：肿瘤 经验分享：杂志一般，类似international journal of surgery，及时if8，希望后续能维持10, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=83912531155, createdName=1250080bm96暂无昵称, createdTime=Fri Dec 20 10:51:30 CST 2024, time=2024-12-20, status=1, ipAttribution=北京)]

2022-11-18 ms8000000534826025

请问大佬们在under review之前有经过pending decision吗

180 4 举报

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2103709, encodeId=819f2103e0902, content=请教大家一个问题，这个杂志编辑部要求上传以前的投稿版本和查重报告，但是PDF格式一直上传不了，大家是怎么解决这个问题的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=210, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27ce8200339, createdName=ms3000001959437613, createdTime=Thu Dec 01 14:06:25 CST 2022, time=2022-12-01, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2233938, encodeId=20572233938c9, content=偏重的研究方向：骨科 经验分享：大伙儿们，这个杂志是提交后状态就是under review吗？已经一个月了，期间也没收到送审的邮件，状态一直是under review, 很焦虑。<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>#clinical and translational medicine#, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=10, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c43b9111664, createdName=ms9000000165099070, createdTime=Tue Oct 29 15:31:03 CST 2024, time=2024-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2198461, encodeId=a741219846107, content=偏重的研究方向：肿瘤;肿瘤临床基础;癌症治疗 经验分享：2024.1.8投稿 under initial checking 2024.1.13变为under review 2024.1.25变为pending recommendation 2024.2.6变为major revision，三个审稿人，两个小修一个大修，编辑给了大修，给了两个月时间。每个审稿人5个左右问题，补了两个大实验，现在已返修回去，求好运…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=235, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ca15460308, createdName=ms3000001338909804, createdTime=Sun Apr 14 16:14:56 CST 2024, time=2024-04-14, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2188951, encodeId=82882188951ff, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：神经系统疾病 经验分享：审稿人偏多，一般5-6个（可能同时找10几个） 01-Nov-2023 submit； 25-Nov-2023 major revision（五个审稿人，给两个月时间）； 30-Jan-2024 revision submit； 19-Feb-2024 minor revision（二审加送一个审稿人）； 21-Feb-2024 revision submit； 22-Feb-2024 accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6a62307215, createdName=科研小白白白白alz, createdTime=Fri Feb 23 18:09:13 CST 2024, time=2024-02-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2255223, encodeId=863c2255223e3, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：速度挺快投稿到接受 4 个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b13f1619698, createdName=ZF2012ZF, createdTime=Sat Mar 08 16:13:50 CST 2025, time=2025-03-08, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2247883, encodeId=b60a224e883d8, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫治疗;非小细胞肺癌;微生物组学 经验分享：Issue Online: 10 January 2025 Version of Record online: 10 January 2025（接收后约20天online） Manuscript accepted: 22 December 2024 Manuscript revised: 09 December 2024 Need Revision: 02 December 2024(二审2个月，增加1位审稿人，8条审稿意见) Under Review: 08 October 2024(一个审稿人，14条审稿意见，相对容易回答) Need Revision: 07 October 2024(一审1个月) Manuscript received: 05 September 2024 整体审稿速度适中，审稿意见相对柔和，较容易回答，一审速度快前提是未找到足够多的审稿人的情况下 APC约2.7wRMB（当日汇率计算），接收后在线proof，约20天online。希望对大家有用。加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f8c1744425, createdName=2122015030, createdTime=Mon Jan 13 14:35:58 CST 2025, time=2025-01-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2101296, encodeId=1ed62101296f2, content=请问大佬们在under review之前有经过pending decision吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b918193010, createdName=ms8000000534826025, createdTime=Fri Nov 18 11:33:30 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2227813, encodeId=c63f222e813de, content=投稿两天，投稿submission status 是under review，但是右边有几行小字写的是This submission is under consideration and cannot be edited. Further information will be emailed to you by the journal editorial office.，求问这是送审了还是还没分配编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d905570358, createdName=ms3000001344629820, createdTime=Thu Sep 26 15:11:46 CST 2024, time=2024-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=953692, encodeId=8aea953692bb, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：第一次投稿没有送外审被编辑直接拒稿但是副编辑给了修改为letter重新投的机会于是修改为letter后重新投稿送外审一审一个月左右小修修回后三天左右接收很快online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=334, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2bf35329265, createdName=148c69cbm40暂无昵称, createdTime=Sat Apr 03 23:54:59 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2243716, encodeId=15f82243e1608, content=偏重的研究方向：肿瘤 经验分享：杂志一般，类似international journal of surgery，及时if8，希望后续能维持10, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=83912531155, createdName=1250080bm96暂无昵称, createdTime=Fri Dec 20 10:51:30 CST 2024, time=2024-12-20, status=1, ipAttribution=北京)]

2024-09-26 ms3000001344629820 来自陕西省

投稿两天，投稿submission status 是under review，但是右边有几行小字写的是This submission is under consideration and cannot be edited. Further information will be emailed to you by the journal editorial office.，求问这是送审了还是还没分配编辑

152 24 举报

展开24条回复

[GetPortalCommentsPageByObjectIdResponse(id=2103709, encodeId=819f2103e0902, content=请教大家一个问题，这个杂志编辑部要求上传以前的投稿版本和查重报告，但是PDF格式一直上传不了，大家是怎么解决这个问题的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=210, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27ce8200339, createdName=ms3000001959437613, createdTime=Thu Dec 01 14:06:25 CST 2022, time=2022-12-01, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2233938, encodeId=20572233938c9, content=偏重的研究方向：骨科 经验分享：大伙儿们，这个杂志是提交后状态就是under review吗？已经一个月了，期间也没收到送审的邮件，状态一直是under review, 很焦虑。<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>#clinical and translational medicine#, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=10, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c43b9111664, createdName=ms9000000165099070, createdTime=Tue Oct 29 15:31:03 CST 2024, time=2024-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2198461, encodeId=a741219846107, content=偏重的研究方向：肿瘤;肿瘤临床基础;癌症治疗 经验分享：2024.1.8投稿 under initial checking 2024.1.13变为under review 2024.1.25变为pending recommendation 2024.2.6变为major revision，三个审稿人，两个小修一个大修，编辑给了大修，给了两个月时间。每个审稿人5个左右问题，补了两个大实验，现在已返修回去，求好运…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=235, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ca15460308, createdName=ms3000001338909804, createdTime=Sun Apr 14 16:14:56 CST 2024, time=2024-04-14, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2188951, encodeId=82882188951ff, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：神经系统疾病 经验分享：审稿人偏多，一般5-6个（可能同时找10几个） 01-Nov-2023 submit； 25-Nov-2023 major revision（五个审稿人，给两个月时间）； 30-Jan-2024 revision submit； 19-Feb-2024 minor revision（二审加送一个审稿人）； 21-Feb-2024 revision submit； 22-Feb-2024 accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6a62307215, createdName=科研小白白白白alz, createdTime=Fri Feb 23 18:09:13 CST 2024, time=2024-02-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2255223, encodeId=863c2255223e3, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：速度挺快投稿到接受 4 个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b13f1619698, createdName=ZF2012ZF, createdTime=Sat Mar 08 16:13:50 CST 2025, time=2025-03-08, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2247883, encodeId=b60a224e883d8, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫治疗;非小细胞肺癌;微生物组学 经验分享：Issue Online: 10 January 2025 Version of Record online: 10 January 2025（接收后约20天online） Manuscript accepted: 22 December 2024 Manuscript revised: 09 December 2024 Need Revision: 02 December 2024(二审2个月，增加1位审稿人，8条审稿意见) Under Review: 08 October 2024(一个审稿人，14条审稿意见，相对容易回答) Need Revision: 07 October 2024(一审1个月) Manuscript received: 05 September 2024 整体审稿速度适中，审稿意见相对柔和，较容易回答，一审速度快前提是未找到足够多的审稿人的情况下 APC约2.7wRMB（当日汇率计算），接收后在线proof，约20天online。希望对大家有用。加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f8c1744425, createdName=2122015030, createdTime=Mon Jan 13 14:35:58 CST 2025, time=2025-01-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2101296, encodeId=1ed62101296f2, content=请问大佬们在under review之前有经过pending decision吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b918193010, createdName=ms8000000534826025, createdTime=Fri Nov 18 11:33:30 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2227813, encodeId=c63f222e813de, content=投稿两天，投稿submission status 是under review，但是右边有几行小字写的是This submission is under consideration and cannot be edited. Further information will be emailed to you by the journal editorial office.，求问这是送审了还是还没分配编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d905570358, createdName=ms3000001344629820, createdTime=Thu Sep 26 15:11:46 CST 2024, time=2024-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=953692, encodeId=8aea953692bb, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：第一次投稿没有送外审被编辑直接拒稿但是副编辑给了修改为letter重新投的机会于是修改为letter后重新投稿送外审一审一个月左右小修修回后三天左右接收很快online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=334, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2bf35329265, createdName=148c69cbm40暂无昵称, createdTime=Sat Apr 03 23:54:59 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2243716, encodeId=15f82243e1608, content=偏重的研究方向：肿瘤 经验分享：杂志一般，类似international journal of surgery，及时if8，希望后续能维持10, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=83912531155, createdName=1250080bm96暂无昵称, createdTime=Fri Dec 20 10:51:30 CST 2024, time=2024-12-20, status=1, ipAttribution=北京)]

2021-04-03 148c69cbm40暂无昵称

审稿速度:2.0 | 投稿命中率:25.0
经验分享：第一次投稿没有送外审被编辑直接拒稿但是副编辑给了修改为letter重新投的机会于是修改为letter后重新投稿送外审一审一个月左右小修修回后三天左右接收很快online

334 12 举报

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=2103709, encodeId=819f2103e0902, content=请教大家一个问题，这个杂志编辑部要求上传以前的投稿版本和查重报告，但是PDF格式一直上传不了，大家是怎么解决这个问题的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=210, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27ce8200339, createdName=ms3000001959437613, createdTime=Thu Dec 01 14:06:25 CST 2022, time=2022-12-01, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2233938, encodeId=20572233938c9, content=偏重的研究方向：骨科 经验分享：大伙儿们，这个杂志是提交后状态就是under review吗？已经一个月了，期间也没收到送审的邮件，状态一直是under review, 很焦虑。<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>#clinical and translational medicine#, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=10, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c43b9111664, createdName=ms9000000165099070, createdTime=Tue Oct 29 15:31:03 CST 2024, time=2024-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2198461, encodeId=a741219846107, content=偏重的研究方向：肿瘤;肿瘤临床基础;癌症治疗 经验分享：2024.1.8投稿 under initial checking 2024.1.13变为under review 2024.1.25变为pending recommendation 2024.2.6变为major revision，三个审稿人，两个小修一个大修，编辑给了大修，给了两个月时间。每个审稿人5个左右问题，补了两个大实验，现在已返修回去，求好运…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=235, replyNumber=19, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ca15460308, createdName=ms3000001338909804, createdTime=Sun Apr 14 16:14:56 CST 2024, time=2024-04-14, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2188951, encodeId=82882188951ff, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：神经系统疾病 经验分享：审稿人偏多，一般5-6个（可能同时找10几个） 01-Nov-2023 submit； 25-Nov-2023 major revision（五个审稿人，给两个月时间）； 30-Jan-2024 revision submit； 19-Feb-2024 minor revision（二审加送一个审稿人）； 21-Feb-2024 revision submit； 22-Feb-2024 accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6a62307215, createdName=科研小白白白白alz, createdTime=Fri Feb 23 18:09:13 CST 2024, time=2024-02-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2255223, encodeId=863c2255223e3, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：速度挺快投稿到接受 4 个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b13f1619698, createdName=ZF2012ZF, createdTime=Sat Mar 08 16:13:50 CST 2025, time=2025-03-08, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2247883, encodeId=b60a224e883d8, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫治疗;非小细胞肺癌;微生物组学 经验分享：Issue Online: 10 January 2025 Version of Record online: 10 January 2025（接收后约20天online） Manuscript accepted: 22 December 2024 Manuscript revised: 09 December 2024 Need Revision: 02 December 2024(二审2个月，增加1位审稿人，8条审稿意见) Under Review: 08 October 2024(一个审稿人，14条审稿意见，相对容易回答) Need Revision: 07 October 2024(一审1个月) Manuscript received: 05 September 2024 整体审稿速度适中，审稿意见相对柔和，较容易回答，一审速度快前提是未找到足够多的审稿人的情况下 APC约2.7wRMB（当日汇率计算），接收后在线proof，约20天online。希望对大家有用。加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f8c1744425, createdName=2122015030, createdTime=Mon Jan 13 14:35:58 CST 2025, time=2025-01-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2101296, encodeId=1ed62101296f2, content=请问大佬们在under review之前有经过pending decision吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b918193010, createdName=ms8000000534826025, createdTime=Fri Nov 18 11:33:30 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2227813, encodeId=c63f222e813de, content=投稿两天，投稿submission status 是under review，但是右边有几行小字写的是This submission is under consideration and cannot be edited. Further information will be emailed to you by the journal editorial office.，求问这是送审了还是还没分配编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=24, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d905570358, createdName=ms3000001344629820, createdTime=Thu Sep 26 15:11:46 CST 2024, time=2024-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=953692, encodeId=8aea953692bb, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：第一次投稿没有送外审被编辑直接拒稿但是副编辑给了修改为letter重新投的机会于是修改为letter后重新投稿送外审一审一个月左右小修修回后三天左右接收很快online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=334, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2bf35329265, createdName=148c69cbm40暂无昵称, createdTime=Sat Apr 03 23:54:59 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2243716, encodeId=15f82243e1608, content=偏重的研究方向：肿瘤 经验分享：杂志一般，类似international journal of surgery，及时if8，希望后续能维持10, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=83912531155, createdName=1250080bm96暂无昵称, createdTime=Fri Dec 20 10:51:30 CST 2024, time=2024-12-20, status=1, ipAttribution=北京)]

2024-12-20 1250080bm96暂无昵称来自北京

偏重的研究方向：肿瘤
经验分享：杂志一般，类似international journal of surgery，及时if8，希望后续能维持10

145 0 举报

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务